RESUMEN
A case report of a HIV seropositive 8-year-old child with vulvar and anal border neoplasia, both grade 3, and the adopted therapeutic management are presented. The mother reported the history of a progressively growing verrucous lesion in the vulva since the age of three and a half years. On physical examination a pigmented and elevated lesion was observed in the whole vulvar region extending to the anal region and intergluteal sulcus. After biopsies and anatomic pathological examination, antiretroviral therapy, adequate for age, and topical application of podophyllotoxin associated with Thuya officinalis extract was started. Three months afterwards vaporization and CO2 laser excision were performed in five sequential sessions, thereafter associated with topical imiquimod application. After the first two sessions of laser therapy early relapses occurred. After four weeks of imiquimod use, already a significant improvement of the lesions was observed, making the following laser therapy sessions easier. We conclude that antiretroviral therapy associated with podophyllotoxin and Thuya was not effective regarding regression of the lesions. Laser therapy alone led to early relapses. The local use of imiquimod associated with laser was effective in decreasing and controling the lesions.
Asunto(s)
Neoplasias del Ano/terapia , Carcinoma/terapia , Infecciones por VIH/diagnóstico , Infecciones por VIH/tratamiento farmacológico , Neoplasias de la Vulva/terapia , Administración Tópica , Aminoquinolinas/administración & dosificación , Fármacos Anti-VIH/uso terapéutico , Neoplasias del Ano/patología , Carcinoma/patología , Niño , Terapia Combinada , Femenino , Estudios de Seguimiento , Infecciones por VIH/inmunología , Seropositividad para VIH , Humanos , Imiquimod , Huésped Inmunocomprometido , Terapia por Luz de Baja Intensidad/métodos , Infecciones por Papillomavirus/patología , Infecciones por Papillomavirus/terapia , Medición de Riesgo , Resultado del Tratamiento , Neoplasias de la Vulva/patologíaRESUMEN
The authors established a protocol for the use of 5-fluorouracil (5FU) adjuvant in lasertherapy for clinical and subclinical HPV infection in immunosuppressed patients, persistent lesions and as reinforcement treatment in cases of poor progress. Sixty-four patients were evaluated, of whom 26 were immunosuppressed, 34 presented persistent lesions and four received intravaginal reinforcement treatment with 2.5 g 5% 5FU every two weeks, or biweekly vulvar reinforcement after lasertherapy. On average, five 5FU courses were used, but in the immunossuppressed patients its use was maintained indefinitely. The rate of complete response was 66%, but the immunossuppressed patients showed less response (46.2%) when compared with the persistent lesion/reinforcement treatment group (78.9%). The responses were positive in the two groups when compared to that with no response. We deem the use of low-dose 5FU an excellent alternative in cases of difficult HPV progress, presenting a low cost and minimal side-effects.